There’s heightened drama in India around remdesivir, Gilead Sciences Inc.’s investigational antiviral currently in the global spotlight as a potential treatment for COVID-19.
While the US firm recently sealed non-exclusive voluntary licensing agreements with five generic firms in India and Pakistan to manufacture remdesivir for distribution in 127 countries, what set the cat among the pigeons was an announcement by a minister in the Indian state of Maharashtra of plans to potentially procure the drug from a firm in Bangladesh
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?